What were the main drivers of Amgen's revenue in the second quarter of 2011?

The filing itself does not provide specific revenue figures or their drivers. Investors should refer to the 'Management's Discussion and Analysis of Financial Condition and Results of Operations' (Item 2) for detailed explanations on product sales performance, which would include the key products contributing to revenue.

Are there any significant legal or regulatory issues that could impact Amgen's financials?

Yes, the filing indicates 'Legal Proceedings' in Item 1 of Part II. Investors should review this section and the 'Risk Factors' (Item 1A) for potential financial implications arising from ongoing litigation or regulatory matters.

What is Amgen's current financial health and liquidity position?

The Condensed Consolidated Balance Sheets and Statements of Cash Flows in Part I, along with the accompanying notes and MD&A, will provide details on Amgen's assets, liabilities, equity, and cash generation activities, which are essential for assessing its financial health and liquidity.

What are the primary risks Amgen faces as outlined in this filing?

The 'Risk Factors' section (Item 1A) is dedicated to detailing the risks faced by Amgen. Investors should carefully review this section to understand potential challenges related to product development, competition, regulatory environments, and other operational factors.

AMGN 10-Q Quarterly Report Q2 FY2011 — Revenue, Net Income, EPS

Summary

Amgen Inc.'s (AMGN) second-quarter 2011 filing for the period ending June 29, 2011, indicates a mixed financial performance. While the company provided detailed financial statements and management's discussion on its results of operations, the filing does not immediately reveal significant year-over-year growth or decline in top-line revenue or profitability without specific figures. Investors should pay close attention to the Management's Discussion and Analysis (MD&A) section for a deeper understanding of the operational drivers, including product sales performance, cost management, and any new developments impacting financial condition. Key areas to scrutinize in the MD&A would include revenue trends for Amgen's key drugs, such as Enbrel, Aranesp, and Neulasta, as well as the impact of any litigation or regulatory challenges, which are mentioned in Part II of the filing. The company's liquidity and capital resources, along with any off-balance sheet arrangements or contingent liabilities, will also be crucial for assessing the company's financial health and future prospects. The filing also touches upon market risk and controls and procedures, providing further context for investors.

Financial Highlights

52 data points

Beta

Revenue

$3.96B

0.8% Gross Margin

Net Income

$1.17B

0.3% Net Margin

EPS (Diluted)

$1.25

Total Assets

$46.94B

Cash & Equivalents

$6.00B

Free Cash Flow

$1.41B

Financial Statements

Beta

Revenue	$3.96B
Gross Profit	$3.29B
SG&A Expenses	$1.13B
Operating Expenses	$2.63B
Operating Income	$1.33B
Interest Expense	$122.00M
Net Income	$1.17B
EPS (Basic)	$1.26
EPS (Diluted)	$1.25
Shares Outstanding (Basic)	927.00M
Shares Outstanding (Diluted)	935.00M

Key Highlights

1The 10-Q filing covers the financial performance for the quarter ending June 29, 2011.
2Part I includes unaudited Condensed Consolidated Financial Statements (Income, Balance Sheets, Cash Flows) and Notes.
3Management's Discussion and Analysis (MD&A) is provided in Item 2, offering insights into financial condition and results of operations.
4Disclosures about market risk are included in Item 3.
5The filing mentions Legal Proceedings in Item 1 of Part II, which could represent potential financial risks or impacts.
6Risk Factors are detailed in Item 1A of Part II, providing a comprehensive overview of potential challenges.
7Information regarding controls and procedures is presented in Item 4 of Part I.

AMGEN INC Quarterly Report for Q2 Ended Jun 30, 2011

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions